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Association of Cardiometabolic MultimorbidityWithMortality
The Emerging Risk Factors Collaboration
IMPORTANCE The prevalence of cardiometabolic multimorbidity is increasing.
OBJECTIVE To estimate reductions in life expectancy associated with cardiometabolic
multimorbidity.
DESIGN, SETTING, AND PARTICIPANTS Age- and sex-adjustedmortality rates and hazard ratios
(HRs) were calculated using individual participant data from the Emerging Risk Factors
Collaboration (689 300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest
mortality follow-up: April 2013; 128 843 deaths). The HRs from the Emerging Risk Factors
Collaboration were compared with those from the UK Biobank (499 808 participants; years
of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths).
Cumulative survival was estimated by applying calculated age-specific HRs for mortality to
contemporary US age-specific death rates.
EXPOSURES A history of 2 or more of the following: diabetes mellitus, stroke, myocardial
infarction (MI).
MAIN OUTCOMES ANDMEASURES All-causemortality and estimated reductions in life
expectancy.
RESULTS In participants in the Emerging Risk Factors Collaboration without a history of
diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to
the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years
were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with
MI, 32.0 in those with both diabetes andMI, 32.5 in those with both diabetes and stroke, 32.8
in those with both stroke andMI, and 59.5 in those with diabetes, stroke, andMI. Compared
with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in
participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI,
1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes andMI, 3.8 (95% CI,
3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke
andMI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, andMI. The HRs from the
Emerging Risk Factors Collaboration were similar to those from themore recently recruited
UK Biobank. The HRs were little changed after further adjustment for markers of established
intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors
(eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was
associated with 12 years of reduced life expectancy and a history of all 3 of these conditions
was associated with 15 years of reduced life expectancy.
CONCLUSIONS AND RELEVANCE Mortality associated with a history of diabetes, stroke, or MI
was similar for each condition. Because any combination of these conditions was associated
with multiplicative mortality risk, life expectancy was substantially lower in people with
multimorbidity.
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T he prevalence of cardiometabolic multimorbidity(defined herein as a history of ≥2 of the following:diabetes mellitus, stroke, myocardial infarction [MI])
is increasing rapidly.1-3 Considerable evidence exists about
the mortality risk of having any 1 of these conditions
alone.4-7 However, evidence is sparse about life expectancy
among people who have 2 or 3 cardiometabolic conditions
concomitantly. Valid estimation of the associations of car-
diometabolic multimorbidity with mortality requires com-
parison of people with multimorbidity with participants
within the same cohorts who did not have any of the condi-
tions at baseline. However, few population cohorts have
had sufficient power, detail, and longevity to enable such
comparisons.8-14
We aimed to provide reliable estimates of the associa-
tions of cardiometabolic multimorbidity with mortality and
reductions in life expectancy. We analyzed individual par-
ticipant data in the Emerging Risk Factors Collaboration
(ERFC) from 689 300 participants recruited during 1960
through 2007 into 91 prospective cohorts that have recorded
mortality during prolonged follow-up. We compared the
ERFC results with those from the UK Biobank, a prospective
cohort study of 499 808 participants recruited during 2006
through 2010.
Methods
Overall Design
Our analysis involved several interrelated components
(eFigure 1 in the Supplement). First, we quantified associa-
tions of cardiometabolic multimorbidity with all-cause mor-
tality. To maximize power, we analyzed data from the ERFC
in which a total of about 129 000 deaths have accrued. Sec-
ond, we compared results from the ERFC with those from
the UK Biobank. The UK Biobank recruited participants
more recently than the ERFC and it had accrued about 8000
deaths at the time of this analysis. Third, we estimated
reductions in life expectancy associated with cardiometa-
bolic multimorbidity by applying results from the ERFC to
contemporary US age-specific death rates. Fourth, we
placed our findings in the context of previous relevant stud-
ies identified through a systematic review.
Data Sources
Both the ERFC and the UK Biobank have been described.15-17
Prospective cohort studies contributing to the ERFC were
included in this analysis if they met all the following crite-
ria: (1) had recruited participants on the basis of informed
consent, (2) had recorded information about the diagnosis
of diabetes, stroke, and MI at the baseline survey, (3) did not
select participants on the basis of having previous chronic
disease (including cardiovascular disease and diabetes),
(4) had recorded cause-specific deaths, and (5) had accrued
more than 1 year of follow-up. Details of the contributing
studies in the ERFC are presented in eTable 1 and eAppen-
dix 2 in the Supplement. Information on the methods used
to characterize diagnosis of diabetes, stroke, and MI at the
baseline survey are presented in eTable 2. The contributing
studies classified deaths according to the primary cause
(or, in its absence, the underlying cause), on the basis of
coding from the International Classification of Diseases,
Eighth-Tenth Revisions, to at least 3 digits, or according to
study-specific classification systems. Classification of
deaths was based on death certificates, which was supple-
mented in 53 studies by medical records, findings on
autopsy, and other sources. The date of the latest mortality
follow-up was April 2013.
In the UK Biobank, information on a baseline history of
diabetes, stroke, and MI was available for 499 808 partici-
pants recruited from 22 centers throughout the United King-
dom (eAppendix 3 in the Supplement). After giving consent,
participants provided biological samples and completed a
touch-screen questionnaire, a computer-assisted interview,
and a physical examination. Participants have been linked
with the death records of the UK Office for National Statis-
tics through National Health Service identification num-
bers. Deaths were classified according to the primary cause
(or, in its absence, the underlying cause), or on the basis of
coding from the International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision, to at
least 3 digits. The date of the latest mortality follow-up was
November 2013.
Details of our systematic reviewof population-basedpro-
spective studies reportedbetweenJanuary 1970andApril 2015
appear in eAppendix 4 in the Supplement. No language re-
strictions were applied to the publications. Studies were not
eligible for the review if they had contributed data to the
ERFC.8,13,18 Two authors (P.W. and L.M.O.K.) extracted and
cross-checked information from publications according to a
prespecified protocol and disagreements were resolved by
a third author (E.D.A.).
Approval was provided by the Cambridgeshire Ethics
Review Committee.
Statistical Analysis
For both the ERFC and the UK Biobank, we categorized par-
ticipants into the following 8 mutually exclusive groups ac-
cording to baseline disease: (1) diabetes, (2) stroke, (3) MI,
(4) diabetes and MI, (5) diabetes and stroke, (6) stroke and
MI, (7) diabetes, stroke, and MI, (8) none of these (reference
group).Weassessedassociationsof thesebaselinegroupswith
the risk of death from any cause.
Hazard ratios (HRs) were calculated using Cox propor-
tional hazards regression models. The principal objective of
our studywas to estimate reductions in life expectancy asso-
ciated with having different combinations of cardiometa-
bolicmultimorbidity. To this end, our primary analysis calcu-
lated HRs stratified by sex and adjusted for age only. A
secondary objectivewas to explore the extent towhichmark-
ers of some established intermediate pathways (ie, total and
high-density lipoprotein cholesterol, blood pressure, body
mass index) and lifestyle factors (ie, smoking, diet, socioeco-
nomic status) couldexplainassociationsbetweencardiometa-
bolic multimorbidity and mortality. To this end, subsidiary
analyses calculated HRs adjusted for these additional fac-
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tors. The HRs in the ERFCwere calculated using a 2-stage ap-
proach,withestimatescalculatedseparatelywithineachstudy
before pooling across studies by random-effects meta-
analysis using an extension of the DerSimonian and Laird
procedure.16,19
Participants were included in the analyses irrespective
of previous nonfatal events. For each specific cause of death,
outcomes were censored if a participant was lost to follow-
up, died of other causes, or reached the end of the follow-up
period. The proportional hazards assumption was satisfied
for all-cause mortality (eFigure 2 in the Supplement). We
used the I2 statistic to quantify between-study heterogeneity
and the Wald test to assess interactions.
Becauseage-specificmortality rates cannotbedirectlyob-
tained from a 2-stage approach using Cox regression models
(ie, thesemodels estimate instantaneousprobabilityofdeath),
weuseda2-levelmixed-effectsPoisson regressionmodelwith
random study intercept adjusted for baseline disease status,
sex and age at risk (linear and quadratic terms), and interac-
tions of age at risk with the preceding variables. This Poisson
regressionmodel was used to obtainmortality rates adjusted
to the age of 60 years (ie, marginal effects).
Detail of the methods used to estimate reductions in life
expectancy is in eAppendix 5 in the Supplement. Briefly,
estimates of cumulative survival from 40 years of age
onward among the 8 baseline disease groups were calcu-
lated by applying the HRs for cause-specific mortality from
the ERFC (specific to age at risk and sex) to the detailed
mortality component of the US Centers for Disease Control
and Prevention’s CDC WONDER database, which recorded
almost 10 million deaths among more than 305 million indi-
viduals during 2007 through 2010.20,21 We modeled results
throughout middle age and old age, giving specific consid-
eration to the HRs with cardiometabolic multimorbidity
recorded by the age of 60 years, the period of life when mul-
timorbidity becomes increasingly common.22 Analyses
involved Stata version 12.0 (StataCorp), 2-sided P values,
and used a significance level of P < .05.
Results
Emerging Risk Factors Collaboration
At baseline, the mean (SD) age was 53 (9) years and 51%were
women (Table 1). The large majority of participants were en-
rolled inEurope (69%)orNorthAmerica (24%) (eTable 1 in the
Supplement).Of689 300participants, 24 677 (3.6%)hadahis-
tory of diabetes at enrollment, 8583 (1.2%) had stroke, 21 591
Table 1. Baseline Characteristics of Participants by Disease Status at Baseline
Disease Status at Baseline
None Diabetes Stroke MI
Diabetes
and MI
Diabetes
and Stroke
Stroke
and MI
Diabetes,
Stroke,
and MI
Emerging Risk Factors Collaboration (91 Studies; 689 300 Participants)
No. (%) of participants 627 518 (91.0) 24 677 (3.6) 8583 (1.2) 21 591 (3.1) 3233 (0.5) 1321 (0.2) 1836 (0.3) 541 (0.1)
Age at survey, mean (SD), y 52.1 (8.9) 57.3 (8.1) 50.9 (7.8) 60.5 (7.0) 69.4 (6.5) 67.7 (6.8) 69.8 (6.9) 63.8 (6.9)
Male sex, No. (%)a 305 031 (49) 12 347 (50) 4496 (52) 14 643 (68) 2121 (66) 738 (56) 1232 (67) 322 (60)
Current smoker, No. (%)a 197 335 (31) 5343 (22) 2086 (24) 5759 (27) 515 (16) 224 (17) 412 (22) 82 (15)
Systolic blood pressure, mean (SD),
mm Hg
132 (19) 141 (21) 142 (22) 139 (22) 142 (22) 150 (22) 144 (23) 146 (22)
Body mass index, mean (SD)b 25.6 (4.2) 27.9 (5.3) 26.3 (4.5) 26.6 (4.3) 30.5 (4.8) 29.0 (5.2) 27.3 (4.5) 28.1 (5.1)
Cholesterol, mean (SD), mmol/L
Total 5.84 (1.12) 5.67 (1.18) 5.85 (1.12) 5.87 (1.15) 5.93 (1.14) 5.70 (1.18) 5.76 (1.14) 5.30 (1.15)
High-density lipoprotein 1.37 (0.39) 1.24 (0.37) 1.33 (0.40) 1.22 (0.36) 1.10 (0.34) 1.15 (0.34) 1.12 (0.37) 1.06 (0.33)
UK Biobank (499 808 Participants)
No. (%) of participants 461 754 (92.4) 18 549 (3.7) 6835 (1.4) 8770 (1.8) 2036 (0.4) 966 (0.2) 668 (0.1) 230 (0.05)
Age at survey, mean (SD), y 56.7 (8.1) 59.6 (7.2) 60.8 (7.0) 62.1 (6.3) 62.7 (5.7) 62.2 (6.2) 62.5 (6.1) 61.7 (6.5)
Male sex, No. (%)c 202 816 (44) 11 184 (60) 3683 (54) 6981 (80) 1709 (84) 627 (65) 500 (75) 178 (77)
Current smoker, No. (%)c 47 771 (10) 1983 (11) 1057 (15) 1249 (14) 277 (14) 131 (14) 145 (22) 55 (24)
Systolic blood pressure, mean (SD),
mm Hg
137 (19) 141 (17) 140 (19) 136 (19) 138 (19) 141 (19) 137 (20) 137 (18)
Body mass index, mean (SD)b 27.2 (4.7) 31.2 (5.9) 28.3 (4.9) 28.8 (4.6) 31.8 (5.4) 31.8 (5.9) 29.3 (5.1) 31.9 (5.3)
Education (vocational or university),
No./Total (%)
278 419/
457 263 (61)
9813/
18 162 (54)
3344/
6746 (50)
4127/
8636 (48)
851/
1989 (43)
409/
945 (43)
281/
657 (43)
89/
224 (40)
Food consumption
Meat (≥2/wk), No. (%)c 301 797 (65) 13 006 (70) 4555 (67) 6154 (70) 1479 (73) 672 (70) 474 (71) 158 (69)
Fruit (≥3/d)c 165 676 (36) 7915 (43) 2393 (35) 2966 (34) 824 (41) 433 (45) 224 (34) 99 (43)
Abbreviation: MI, myocardial infarction.
SI conversion factors: To convert high-density lipoprotein and total cholesterol
to mg/dL, divide by 0.0259.
a The denominators used to calculate the percentages are in row 2 of this Table.
b Calculated as weight in kilograms divided by height in meters squared.
c The denominators used to calculate the percentages are in row 12 of this
Table.
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(3.1%) hadMI, 3233 (0.5%) had a history of both diabetes and
MI, 1321 (0.2%) had both diabetes and stroke, 1836 (0.3%) had
both stroke and MI, and 541 (0.1%) had diabetes, stroke, and
MI. Therewere 128 843deaths (50 595due to vascular causes;
39 266, cancer; 30 664, other causes; and 8318, unknown or
ill-definedcauses)during8.83millionperson-yearsat risk (me-
dian follow-up, 12.8 years; 5th-95thpercentile, 4.0-29.5 years)
(eTable 1).
In the reference group, the sex-adjusted mortality rate at
the age of 60 years was 6.8 (95% CI, 6.2-7.4) per 1000 person-
years at risk. By contrast, the age- and sex-adjustedmortality
rates were 15.6 (95% CI, 14.1-17.0) in participants with a his-
tory of diabetes, 16.1 (95% CI, 14.4-17.8) in those with stroke,
16.8 (95% CI, 15.2-18.3) in those with MI, 32.0 (95% CI, 28.1-
35.9) in those with a history of both diabetes and MI, 32.5
(95% CI, 27.0-37.9) in those with both diabetes and stroke,
32.8 (95% CI, 28.1-37.6) in those with both stroke and MI,
and 59.5 (95% CI, 47.0-71.9) in those with diabetes, stroke,
and MI (Figure 1).
Compared with the reference group, the age- and sex-
adjusted HRs for mortality were 1.9 (95% CI, 1.8-2.0) for par-
ticipants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in
those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7
(95% CI, 3.3-4.1) in those with a history of both diabetes and
MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and
stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and
MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke,
and MI (Figure 1).
The HRs for participants with a history of 2 or more con-
ditions were generally consistent with multiplicative effects
(P > .05 fordeviation frommultiplicative effects),with the ex-
ception of the HR for those with a history of both stroke and
MI (P < .001). TheHRswere stronger amongwomen thanmen
forparticipantswithdiabetesonly, strokeonly, and thosewith
both diabetes andMI (P < .001; eFigure 3 in the Supplement).
The HRs were little changed after additional adjustment for
smoking (Table 2). The HRs attenuated slightly after further
adjustment for total and high-density lipoprotein choles-
terol, systolic blood pressure, and body mass index. In par-
ticipants with all 3 conditions at baseline, the age- and sex-
adjusted HRs were 11.8 (95% CI, 9.6-14.6) for cardiovascular
mortality, 2.1 (95%CI, 1.5-2.9) for cancermortality, and7.9 (95%
CI, 6.6-9.6) for theaggregateofnonvascular, noncancerdeaths
(eFigure 4).
Broadly similar HRs to those noted above were observed
in analyses that (1) usedalternativedefinitionsof baselinedis-
ease (eFigure 5 in the Supplement), (2)were restricted to stud-
ies that supplemented death certificates with additional in-
formation (eFigure 6), (3) excluded the initial 5 years of
follow-up (eFigure 7), or (4) used fixed-effect meta-analysis
(eFigure 8). The HRs for mortality appeared to decline some-
what with increasing calendar year of baseline study enroll-
ment (eFigure 9).
UKBiobank
At baseline, themean (SD) age was 57 (8) years and 55%were
women (Table 1). Of 499 808 participants, 18 549 (3.7%) had
ahistoryofdiabetesatenrollment,6835 (1.4%)hadstroke,8770
(1.8%) hadMI, 2036 (0.4%) had a history of both diabetes and
MI, 966 (0.2%) had both diabetes and stroke, 688 (0.1%) had
both stroke andMI, and230 (0.05%)haddiabetes, stroke, and
MI. There were 7995 deaths during 2.39 million person-years
at risk (median follow-up, 4.8 years; interquartile range, 4.1-
5.5 years).
Compared with the reference group, the age- and sex-
adjusted HRs for mortality were 1.6 (95% CI, 1.5-1.8) for par-
ticipants with diabetes, 2.1 (95% CI, 1.9-2.4) for those with
stroke, 2.1 (95% CI, 1.9-2.3) for those with MI, 4.3 (95% CI,
3.7-5.0) for those with both diabetes and MI, 3.9 (95% CI, 3.1-
4.9) for those with both diabetes and stroke, 3.8 (95% CI,
2.9-4.9) for those with both stroke and MI, and 6.0 (95% CI,
4.2-8.7) for those with diabetes, stroke, and MI (Figure 2 and
eTable 3 in the Supplement). The HRs were little changed
after additional adjustment for smoking, systolic blood
pressure, body mass index, diet, and socioeconomic status
(Table 2).
Figure 1. All-CauseMortality for the Emerging Risk Factors Collaboration by Disease Status of Participants at Baseline
Disease Status
at Baseline
Stroke and MI
Diabetes and stroke
Diabetes and MI
Diabetes, stroke, and MI
MI 
Stroke
Diabetes
None
Person-
Years
14 210
10 234
25 321
3584
216 081
82 208
254 608
8 772 977
No. of
Deaths
1174
778
1794
379
9636
3814
8087
103 181
No of.
Participants
1836
1321
3233
541
21 591
8583
24 677
627 518
0 806040
Mortality Rate
per 1000 Person-Years
(95% CI)
20
Mortality Rate
(95% CI)a
32.8 (28.1-37.6)
32.5 (27.0-37.9)
32.0 (28.1-35.9)
59.5 (47.0-71.9)
16.8 (15.2-18.3)
16.1 (14.4-17.8)
15.6 (14.1-17.0)
6.8 (6.2-7.4)
1 8 164
Hazard Ratio
(95% CI)
2
Hazard Ratio
(95% CI)
3.5 (3.1-4.0)
3.8 (3.5-4.2)
3.7 (3.3-4.1)
6.9 (5.7-8.3)
2.0 (1.9-2.2)
2.1 (2.0-2.2)
1.9 (1.8-2.0)
1 [Reference]
I2 (95% CI)
61 (52-69)
18 (0-38)
69 (62-75)
51 (38-62)
84 (80-86)
50 (36-61)
76 (70-80)
Themortality rates were calculated using a Poisson regressionmodel and are sex-adjusted rates to the age of 60 years. The hazard ratios were calculated using
a Cox proportional hazards regressionmodel and are stratified by sex and adjusted by age at baseline. Analyses were based on participants from 91 studies.
MI indicates myocardial infarction.
a Mortality rate is per 1000 person-years.
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Estimated Reductions in Life Expectancy
Weestimated that at the ageof 60years,menwith any2of the
cardiometabolic conditionswestudiedwouldonaveragehave
12 years of reduced life expectancy, andmenwith all 3 condi-
tionswouldhave 14years of reduced life expectancy (Figure 3
and eTable 4 in the Supplement). For women at the age of 60
years, the corresponding estimateswere 13 years and 16 years
of life lost. When calculated for patients at younger ages, es-
timated reductions in life expectancy were greater than for
older patients (eg, 23 years of lifewere estimated to be lost for
menat age40yearswith 3 conditions comparedwith 20years
of life lost for men at age 50 years with 3 conditions). Esti-
mated reductions in life expectancy in patients with MI only
weregreater formen thanwomen; estimated reductions in life
expectancy in patients with diabetes only were greater for
women (Figure 3 and eTable 4).
On average, about 59% of the survival difference associ-
ated with cardiometabolic multimorbidity in men was
attributed to excess cardiovascular deaths, and the remain-
der to excess nonvascular, noncancer deaths (36%), cancer
deaths (4%), and unclassified deaths (1%). By contrast, for
women, 45% of the estimated survival difference was attrib-
uted to excess cardiovascular deaths, and the remainder by
nonvascular, noncancer deaths (49%), excess cancer deaths
(5%), and unclassified deaths (2%) (eFigure 10 in the Supple-
ment). Broadly similar results were observed when model-
ing involved cause-specific death rates from the European
Union (eFigure 11).
Systematic Review
We could not identify any previous relevant reports of all-
causemortality that had investigated participants having the
combination of diabetes, stroke, and MI, or any previous rel-
evant reports of participantshaving the combinationof stroke
and MI. We identified only 1 previous relevant report on the
combination of diabetes and stroke, albeit of limited statisti-
cal power.23 By contrast, we identified 5 previous reports on
the combination of diabetes andMI, which generally yielded
similarHRs as in the current analysis (Figure 2 and eTable 5 in
the Supplement), although none estimated reductions in life
expectancy associated with such multimorbidity.9-12,14
Discussion
Our analysis ofmore than 135 000deaths accruedduringpro-
longed follow-up of almost 1.2million participants in popula-
tion cohorts has provided estimates of reductions in life ex-
pectancy associated with different combinations of
cardiometabolic multimorbidity (ie, a history of diabetes,
stroke, and/or MI). Each of our 3 main findings has potential
implications.
First, in patients who had only 1 condition that we stud-
ied, we observed an HR for mortality of about 2; for a combi-
nation of any 2 conditions, the HR was about 4; and for a
combination of all 3 conditions, the HR was about 8. These
results suggest that associations of cardiovascular disease
Table 2. All-CauseMortality in ParticipantsWith Information on Cardiovascular Risk Factors andOther Characteristics
Disease Status at Baseline No. of Participants No. of Deaths
Hazard Ratio (95% CI)
Age and Sex
Age, Sex,
and Smoking
Age, Sex, Smoking,
and Intermediate
Risk Factors
Age, Sex, Smoking,
Intermediate Risk Factors,
and Other Lifestyle Factors
Emerging Risk Factors Collaboration (68 Studies, 355 639 Participants, 47 067 Deaths)a
Diabetes, stroke, and MI 260 165 6.2 (5.1-7.4) 6.3 (5.2-7.5) 6.0 (5.0-7.1)
Stroke and MI 921 517 3.7 (3.1-4.3) 3.8 (3.2-4.4) 3.7 (3.2-4.4)
Diabetes and stroke 654 334 3.7 (3.3-4.2) 3.9 (3.4-4.4) 3.6 (3.2-4.1)
Diabetes and MI 1827 930 3.6 (3.1-4.0) 3.8 (3.3-4.4) 3.6 (3.2-4.1)
MI 12 141 4270 2.0 (1.9-2.1) 2.0 (1.9-2.2) 2.0 (1.9-2.2)
Stroke 4357 1530 2.1 (1.9-2.2) 2.0 (1.9-2.2) 2.0 (1.8-2.1)
Diabetes 12 887 3629 1.9 (1.7-2.0) 1.9 (1.8-2.0) 1.8 (1.7-1.9)
None 322 592 35 692 1 [Reference] 1 [Reference] 1 [Reference]
UK Biobank (491 424 Participants, 7688 Deaths)b
Diabetes, stroke, and MI 218 26 5.8 (3.9-8.5) 5.2 (3.5-7.7) 4.9 (3.3-7.2) 4.9 (3.3-7.2)
Stroke and MI 638 51 3.6 (2.7-4.7) 3.2 (2.5-4.3) 3.1 (2.4-4.1) 3.1 (2.3-4.0)
Diabetes and stroke 919 75 3.9 (3.1-4.9) 3.8 (3.0-4.8) 3.6 (2.9-4.5) 3.6 (2.8-4.5)
Diabetes and MI 1943 190 4.3 (3.7-5.0) 4.2 (3.6-4.8) 4.0 (3.4-4.6) 3.9 (3.4-4.5)
MI 8572 407 2.1 (1.9-2.3) 2.0 (1.8-2.3) 2.0 (1.8-2.2) 2.0 (1.8-2.2)
Stroke 6632 259 2.1 (1.8-2.4) 2.0 (1.8-2.3) 2.0 (1.7-2.2) 1.9 (1.7-2.2)
Diabetes 17 928 504 1.6 (1.5-1.8) 1.6 (1.5-1.8) 1.5 (1.4-1.7) 1.5 (1.4-1.7)
None 454 574 6176 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
Abbreviation: MI, myocardial infarction.
a The intermediate risk factors available were bodymass index; systolic blood
pressure; and high-density lipoprotein and total cholesterol.
b The intermediate risk factors available were bodymass index and systolic
blood pressure. Other lifestyle factors available were socioeconomic status
(defined as education level) and diet (defined as self-reported consumption
of meat and fruit).
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and diabetes with mortality are multiplicative and essen-
tially nonoverlapping. This finding is consistent with previ-
ous observations that associations of diabetes with chronic
disease outcomes are largely independent of major cardio-
vascular risk factors.5,24 Consequently, our results empha-
size the importance of measures to prevent cardiovascular
disease in people who already have diabetes, and, con-
versely, to avert diabetes in people who already have cardio-
vascular disease.25,26
Second, our results suggest that estimated reductions in
life expectancy associated with cardiometabolic multimor-
bidity are of similar magnitude to those previously noted for
exposures of major concern to public health, such as lifelong
smoking (10 years of reduced life expectancy27) and infection
with thehuman immunodeficiency virus (11 years of reduced
life expectancy28,29). For example, cardiometabolicmultimor-
bidity at the age of 60 years was associated with an average
reduction in life expectancy of about 15 years. We estimated
evengreater reductions in lifeexpectancy inpatientswithmul-
timorbidity at younger ages, such as 23 years of life lost in pa-
tients with 3 conditions at the age of 40 years.
Third, we noted modification by sex of associations
between cardiometabolic multimorbidity and mortality. For
men, the association between baseline cardiovascular dis-
ease (ie, a history of stroke or MI) and reduced survival was
stronger than for women, whereas the association between
baseline diabetes and reduced survival was stronger for
women. Consequently, about 60% of the years of life lost
from cardiometabolic multimorbidity can be attributed to
cardiovascular deaths for men compared with only about
45% for women. Nevertheless, for both men and women,
our findings indicate that associations of cardiometabolic
multimorbidity extend beyond cardiovascular mortality.
Future work will seek to elucidate explanations for these
interactions by sex.
Our results highlight the need to balance the primary
prevention and secondary prevention of cardiovascular dis-
ease. About 1% of the participants in the cohorts we studied
had cardiometabolic multimorbidity compared with an esti-
mate of 3% from recent surveys in the United States.30,31
There are currently an estimated 10 million adults in the
United States and the European Union with cardiometabolic
Figure 2. All-CauseMortality From the Emerging Risk Factors Collaboration ComparedWith the UK Biobank and Previous Reports
1 8 164
Hazard Ratio (95% CI)
2
Diabetes, stroke, and MI
Current analysis
1960-2007 2013 685 849 128 293Emerging Risk Factors Collaborationa 6.9 (5.7-8.3)
2006-2010 2013 499 808 7995UK Biobanka 6.0 (4.2-8.7)
Disease Status
at Baseline
No. of
Participants
Date of Last
Follow-up 
Date of
Baseline
No. of
Deaths
Hazard Ratio
(95% CI)
Stroke and MI
Current analysis
1960-2007 2013 685 849 128 293Emerging Risk Factors Collaborationa 3.5 (3.1-4.0)
2006-2010 2013 499 808 7995UK Biobanka 3.8 (2.9-4.9)
Diabetes and MI
Current analysis
1960-2007 2013 685 849 128 293Emerging Risk Factors Collaborationa 3.7 (3.3-4.1)
2006-2010 2013 499 808 7995UK Biobanka 4.3 (3.7-5.0)
Previous analysisb
1982-1983 1988 91 285 3627Physicians’ Health Study10,c 4.7 (4.0-5.4)
1997 2002 3 274 472 287 471Schramm et al9 3.0 (2.9-3.0)
1972-1997 2001 51 735 9201FINRISK Study11 3.9 (3.2-4.8)
Diabetes and stroke
Current analysis
1960-2007 2013 685 849 128 293Emerging Risk Factors Collaborationa 3.8 (3.5-4.2)
2006-2010 2013 499 808 7995UK Biobanka 3.9 (3.1-4.9)
Previous analysisb
1993-1994 1999 3050 629Hispanic Established Population
for the Epidemiological Study
of the Elderly23
2.4 (1.7-3.5)
1986 1996 51 316 4150Health Professionals Follow-up
Study12,c
4.2 (3.4-5.1)
1976 1996 121 046 8464Nurses’ Health Study14,c 6.8 (4.7-10.0)
The hazard ratios were adjusted for sex when appropriate and age, except those
for the Hispanic Established Population for the Epidemiological Study of the
Elderly, which were adjusted for additional variables. MI indicates myocardial
infarction. The size of the data markers is proportional to the information
content in each study.
a For participant-level analyses in the Emerging Risk Factors Collaboration and
the UK Biobank, participants with the disease status indicated at baseline have
been compared with participants within the same cohorts without diabetes,
stroke, or myocardial infarction at baseline.
b For previously published studies, participants with cardiometabolic
multimorbidity at baseline were compared with participants without any such
conditions.
c Used history of coronary heart disease instead of history of MI.
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multimorbidity.1,3,20,21 Nevertheless, an overemphasis on
the substantial reductions in life expectancy estimated
for the subpopulation with multimorbidity could divert
attention and resources away from population-wide strate-
gies that aim to improve health for the large majority of the
population.32
Our study had potential limitations. Our definition of
cardiometabolic multimorbidity was both pragmatically
motivated (we had information available on a history of dia-
betes, stroke, and MI) and biologically motivated (we pur-
posefully focused on binary disease states). However, we
did not include a history of hypertension in our definition of
multimorbidity because categorizing elevated blood pres-
sure as a binary variable would necessarily underestimate
the true effect of blood pressure on chronic disease because
blood pressure has a continuous log-linear relationship with
the risk of cardiovascular diseases throughout its range of
values.33 Furthermore, inclusion of hypertension in our
definition would have created 16 possible disease combina-
tions, which are too many for stable analyses even in the
ERFC. We did not have access to time-varying exposure
information to enable updating of multimorbidity status
during follow-up. Only subsets of participants had informa-
tion on some covariates, such as medication use, and dates
of diagnosis of baseline conditions.
Thegeneralizabilityofourresultswasenhancedbyinvolve-
ment in the ERFC of individual participant data from 91 co-
horts in 18 different countries that recruited participants dur-
ing1960through2007.TowhatextentdotheHRsfromtheERFC
reflect the contemporary situation? Our study addressed this
concern in several ways.We analyzed data in the ERFC by cal-
endar decade, and we did not find evidence of large differ-
ences in the HRs by calendar period of recruitment. We noted
broadly similar findings between the ERFC and the UK
Biobank,whichrecruitedparticipantsduring2006through2010.
Our systematic review found that the HRs reported in previ-
ous relevant publications were compatible with those in the
ERFC, althoughprevious datawere sparse. In addition, for the
survival modeling, we applied the HRs observed in the ERFC
to the death rates derived from the contemporary US popula-
tion and secondarily to the European Union population.
Conclusions
Mortality associated with a history of diabetes, stroke, or MI
was similar for each condition. Because any combination of
these conditions was associated with multiplicative mortal-
ity risk, life expectancywas substantially lower inpeoplewith
multimorbidity.
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